Stockhouse6d
Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett's Esophagus Test
TissueCypher is Castle’s precision medicine risk-stratification test that predicts a patient’s individual risk of progression from Barrett’s esophagus .
News Medical5d
LABORIE's T-DOC Air-Charged Anorectal Manometry Catheter
The T-DOC ® Air-Charged™ ARM Catheter is designed with directional sensors and advanced membrane technology that communicate motility readings ... with more consistent study tracings.
BioSpace6d
Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test
TissueCypher is Castle’s precision medicine risk-stratification test that predicts a patient’s individual risk of progression from Barrett’s esophagus (BE ... subsequent study or trial results and ...
Le Lézard6d
Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett's Esophagus Test
decisions that could ultimately prevent an esophageal ... study, including with respect to the discussion of TissueCypher in this press release; actual application of our TissueCypher test may ...
Medscape3d
Pharmacokinetic Considerations in Roux-en-Y Gastric Bypass Patients
Since the entire duodenum and proximal jejunum are bypassed and motility through the intestine may be increased, 9,10 these drugs may not have adequate transit time for full dissolution and ...
standard-journal6d
Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a significant milestone for the Company’s TissueCypher Barrett’s ...